Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Astrana Health, Inc. (ASTH) and U.S. Physical Therapy (USPH) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive e ...

Astrana Health, Inc. (ASTH) came out with quarterly earnings of $0.19 per share, missing the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.4 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -47.22%. A quarter ago, it was expected that this company would post earnings of $0.23 per share when it actually produced earnings of $0.14, delivering a surprise of -39.13%.Over the last four quarters, the co ...

Astrana Health (ASTH) Q2 2025 Earnings Call August 07, 2025 05:30 PM ET Speaker0Good day, everyone, and welcome to today's Astrana Health Second Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the question and answer session and instructions will be provided at that time. Today's speakers will be Brandon Sim, President and Chief Executive Officer of Astrana Health and John Bachow, Chief Operating ...

Financial Performance - Q2 2025 - Revenue reached $654.8 million[9], a 35% increase compared to Q2 2024's $486.3 million[30] - Adjusted EBITDA was $48.1 million[9], slightly up from $47.917 million in Q2 2024[30] - Net income attributable to Astrana Health was $9.4 million[9], compared to $19.171 million in Q2 2024[30] - EPS-Diluted was $0.19[9], down from $0.40 in Q2 2024[30] FY2025 Guidance - Total revenue is projected to be in the range of $3.1 billion to $3.3 billion[11] - Adjusted EBITDA is expected to be between $215 million and $225 million[11] Business Growth & Risk Management - Astrana Health now serves over 1.6 million patients in value-based arrangements following the acquisition of Prospect[13] - Care Partners segment has 1.4 million members pro forma[13] - 78% of revenues are from fully capitated arrangements, compared to 60% a year ago[13] - The company anticipates 75-85% of capitation revenue from full-risk arrangements exiting 2025[20]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File No. 001-37392 Astrana Health, Inc. (Exact name of registrant as specified in its charter) Delaware 95-4472349 (State or Other Jurisdiction (I. ...

Core Viewpoint - Astrana Health, Inc. (ASTH) is currently positioned as a better value investment compared to Chemed (CHE) based on Zacks Rank and various valuation metrics [3][7]. Valuation Metrics - ASTH has a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook, while CHE has a Zacks Rank of 4 (Sell) [3]. - The forward P/E ratio for ASTH is 14.68, significantly lower than CHE's forward P/E of 20.43, suggesting that ASTH is undervalued relative to CHE [5]. - ASTH's PEG ratio is 0.85, indicating better expected earnings growth compared to CHE's PEG ratio of 2.09, which suggests overvaluation [5]. - ASTH has a P/B ratio of 1.74, while CHE's P/B ratio is 5.83, further indicating that ASTH is more attractively priced [6]. Value Grades - ASTH has received a Value grade of A, reflecting its strong valuation metrics, whereas CHE has a Value grade of C, indicating it is less favorable for value investors [6].

Company Overview - Astrana Health, Inc. is a leading provider-centric, technology-powered healthcare company focused on delivering accessible, high-quality, and high-value care [1][4] - The company supports over 20,000 providers and more than 1.6 million patients in value-based care arrangements through its affiliated networks and integrated care delivery clinics [5] Financial Results Announcement - Astrana Health will release its financial results for the second quarter ended June 30, 2025, after the stock market closes on August 7, 2025 [1] - A conference call to discuss these results will take place at 2:30 p.m. PT/5:30 p.m. ET on the same day [1] Accessing the Conference Call - Participants can dial in to the conference call using the numbers 877-858-9810 or +1 201-689-8517, and should join approximately five minutes before the start time [2] - An accompanying slide presentation will be available in PDF format on the company's Investor Relations website after the earnings release [2] Webcast Availability - The conference call will also be accessible via an online webcast, with a recording available shortly after the call concludes [3]

Core Viewpoint - Astrana Health, Inc. (ASTH) shows significant upside potential with a mean price target of $49.56, indicating a 97.3% increase from the current price of $25.12 [1] Price Targets and Analyst Consensus - The average price target consists of nine estimates ranging from a low of $36.00 to a high of $70.00, with a standard deviation of $12.39, suggesting variability in analyst opinions [2] - The lowest estimate indicates a potential increase of 43.3%, while the highest suggests a 178.7% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about ASTH's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, two estimates have been revised upward, leading to a 46.4% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - ASTH holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Astrana Health, Inc. (ASTH) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Astrana Health, Inc. is expected to earn $1.59 per share for the fiscal year ending December 2025, with no year-over-year change, but the Zacks Consensus Estimate has increased by 19.5% over the past three months [8]. Institutional Investor Influence - Institutional investors utilize earnings estimates to determine the fair value of stocks, and changes in these estimates can lead to significant buying or selling actions, impacting stock prices [4][5]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Astrana Health, Inc. to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting potential for higher stock movement in the near term [10].

Core Viewpoint - Investors in the Medical - Outpatient and Home Healthcare sector should consider Astrana Health, Inc. (ASTH) as a potentially better value option compared to Chemed (CHE) based on various financial metrics and rankings [1]. Group 1: Zacks Rank and Earnings Outlook - Astrana Health, Inc. has a Zacks Rank of 1 (Strong Buy), indicating a positive earnings estimate revision trend, while Chemed has a Zacks Rank of 4 (Sell) [3]. - The improving earnings outlook for ASTH suggests a favorable investment opportunity compared to CHE [7]. Group 2: Valuation Metrics - ASTH has a forward P/E ratio of 15.66, significantly lower than CHE's forward P/E of 20.47, indicating that ASTH may be undervalued [5]. - The PEG ratio for ASTH is 0.91, while CHE's PEG ratio is 2.09, further suggesting that ASTH offers better value considering expected earnings growth [5]. - ASTH's P/B ratio is 1.85 compared to CHE's P/B of 5.84, reinforcing the notion that ASTH is more attractively priced relative to its book value [6]. - Based on these metrics, ASTH has earned a Value grade of A, while CHE has a Value grade of C [6].